ModifiedConnectiCarePolicy AHS-G2153

Pancreatic Enzyme Testing for Acute Pancreatitis

Customize your policy alerts

Sign up for ConnectiCare Policy AHS-G2153 alerts

Get alerted when Policy AHS-G2153 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs ConnectiCare coverage and reimbursement criteria for pancreatic enzyme and related biomarker testing used in evaluating acute pancreatitis. Coverage criteria do not apply to Exchange Plans for dates of service on or after January 1, 2026.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedConnectiCarePolicy AHS-G2153

Pancreatic Enzyme Testing for Acute Pancreatitis

Customize your policy alerts

Sign up for ConnectiCare Policy AHS-G2153 alerts

Get alerted when Policy AHS-G2153 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerConnectiCare

PolicyPancreatic Enzyme Testing for Acute Pancreatitis

Policy CodePolicy AHS-G2153

Change TypeModified

Effective DateSeptember 15, 2026

Next Review DateNot specified

Key ActionOrder serum lipase for patients presenting with signs and symptoms of acute pancreatitis, with no more than one outpatient test per day.

SourceLink

POLICY UPDATE CHANGES

Policy criteria are not applicable to Exchange Plans for dates of service on or after January 1, 2026.

Effective September 15, 2026, coverage criterion 1 was revised to cover serum lipase for individuals presenting with signs and symptoms of acute pancreatitis, limited to no more than one test per day in the outpatient setting.

The amylase criterion was revised to address analysis of pancreatic cyst fluid rather than serum amylase.

Measurement of serum amylase for purposes other than analysis of pancreatic cyst fluid was designated as not meeting coverage criteria.

CPT code 86141 was added to the applicable state and federal regulations section.

The policy background, guidelines and recommendations, and evidence-based scientific references were updated following literature review.

The policy content was transferred to a ConnectiCare-branded template without changes to the policy title or policy number.

1/dayMaximum outpatient serum lipase tests meeting coverage criteria

2 of 3Diagnostic features required for acute pancreatitis

≥3× ULNEnzyme threshold supporting acute pancreatitis diagnosis

LipasePreferred initial pancreatic enzyme test

ExcludedExchange Plan applicability

Coverage Criteria

Serum Lipase Testing

Covered when the individual presents with signs and symptoms of acute pancreatitis.

Measurement of serum lipase.No more than 1 test per day in the outpatient setting.

Pancreatic Cyst Fluid Amylase

Covered only when the specimen is pancreatic cyst fluid.

Measurement of amylase in pancreatic cyst fluid.

Trypsin, Trypsinogen, and TAP

The following testing does not meet coverage criteria for the diagnosis, assessment, prognosis, or determination of severity of acute pancreatitis.

ANY of the following

Measurement of serum trypsin.
Measurement of urine trypsin.
Measurement of serum trypsinogen.
Measurement of urine trypsinogen.
Measurement of serum or urine trypsinogen activation peptide (TAP).

CRP, IL-6, IL-8, and Procalcitonin

The following biomarkers do not meet coverage criteria for the diagnosis, assessment, prognosis, or determination of severity of acute pancreatitis.

ANY of the following

C-Reactive Protein (CRP).
Interleukin-6 (IL-6).
Interleukin-8 (IL-8).
Procalcitonin.

Serum Lipase Outside the Covered Indication

The testing does not meet coverage criteria when performed for situations or conditions other than the covered indication.

Measurement of serum lipase for any situation or condition not described as a covered indication above.

Diagnostic Criteria for Acute Pancreatitis

The diagnosis of acute pancreatitis requires at least 2 of the following 3 criteria.

At least 2 of 3

Abdominal pain not attributable to another cause or suggestive of acute pancreatitis.
Serum amylase or serum lipase at least 3 times the upper limit of normal.>= 3x the upper limit of normal
Imaging findings consistent with acute pancreatitis.

Initial Pancreatic Enzyme Testing

For initial evaluation of suspected acute pancreatitis:

ALL of the following

Use serum lipase in preference to total or pancreatic amylase for initial diagnosis.
Do not order both amylase and lipase routinely; simultaneous testing is generally discouraged because it increases costs while only marginally improving diagnostic efficiency compared with lipase alone.
Amylase may be considered when serum lipase is unavailable as a stat test and the patient has sudden-onset abdominal pain with nausea and vomiting, fever, hypotension, and abdominal distension.

Repeat Testing and Monitoring

Repeat testing should be based on a new clinical diagnostic concern, not routine monitoring.

Repeat testing may be considered when ANY of the following applies

Signs or symptoms suggest persistent pancreatic or peripancreatic inflammation.
There is concern for blockage of the pancreatic duct.
There is concern for development of a pseudocyst.
There is clinical suspicion of acute-on-chronic pancreatitis.

Do not routinely repeat lipase to monitor a patient with an established diagnosis of acute or chronic pancreatitis.

In outpatient or community settings, laboratories may consider a 6-month hard-stop minimum retesting interval to reduce unnecessary retesting.

Revised Covered Criterion: Serum Lipase

The revised covered criterion is:

For individuals presenting with signs and symptoms of acute pancreatitis, measurement of serum lipase.No more than 1 test per day in the outpatient setting.

Revised Covered Criterion: Pancreatic Cyst Fluid Amylase

The revised covered criterion is:

Measurement of amylase when ordered for analysis of pancreatic cyst fluid.

COVERAGE CRITERIA: When ordered for anything other than analysis of pancreatic cyst fluid, measurement of amylase does not meet coverage criteria. This includes serum and urine amylase testing.

COVERAGE CRITERIA: For the diagnosis, assessment, prognosis, and/or determination of severity of acute pancreatitis, measurement of serum or urine trypsin, trypsinogen, or trypsinogen activation peptide (TAP) does not meet coverage criteria.

COVERAGE CRITERIA: For the diagnosis, assessment, prognosis, and/or determination of severity of acute pancreatitis, measurement of C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-8 (IL-8), or procalcitonin does not meet coverage criteria.

COVERAGE CRITERIA: Policy criteria are not applicable to Exchange Plans for dates of service on or after January 1, 2026.

COVERAGE CRITERIA: Routine repeat lipase testing is not recommended for monitoring patients with an established diagnosis of acute or chronic pancreatitis. Repeat testing should be considered only when there is a new diagnostic concern, including persistent pancreatic or peripancreatic inflammation, pancreatic duct obstruction, pseudocyst development, or suspected acute-on-chronic pancreatitis.

COVERAGE CRITERIA: Simultaneous amylase and lipase testing is generally discouraged because it increases costs while only marginally improving diagnostic efficiency compared with lipase alone. Serum lipase is preferred for the initial diagnosis of acute pancreatitis.

COVERAGE CRITERIA: Policy criteria are not applicable to Exchange Plans for dates of service on or after January 1, 2026.

COVERAGE CRITERIA: Serum amylase does not meet coverage criteria except when the amylase is measured from pancreatic cyst fluid. Other amylase testing, including urine amylase, is not covered.

COVERAGE CRITERIA: Policy criteria are not applicable to Exchange Plans for dates of service on or after January 1, 2026.

Coding and Clinical Thresholds

Applicable CPT/HCPCS Procedure CodesCPT

82150	Amylase
83519	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
83529	Interleukin-6 (IL-6)
83690	Lipase
84145	Procalcitonin (PCT)
86140	C-reactive protein
86141	C-reactive protein; high sensitivity (hsCRP)

Applicable State and Federal RegulationsCPT

86141

CPT code 86141

Acute pancreatitis enzyme diagnostic threshold

Diagnostic enzyme thresholdSerum lipase or amylase activity at least 3 times greater than the upper limit of normal

Diagnostic frameworkPart of the revised Atlanta classification for acute pancreatitis

Required accompanying findingsAt least two of three criteria are required, including characteristic abdominal pain, enzyme elevation, or compatible imaging

Pancreatic enzyme elevation for acute pancreatitis

Enzyme elevation thresholdAt least 3 times the upper limit of the reference interval

Test optionsSerum lipase or serum amylase

Provider and Billing Actions

Denial Risk

Lipase Coverage Restriction

Serum lipase is covered only when ordered for individuals presenting with signs and symptoms of acute pancreatitis. Measurement of serum lipase for all other situations or conditions does not meet coverage criteria.

Do not bill serum lipase as covered when the patient is not being evaluated for suspected acute pancreatitis.

Denial Risk

Amylase Coverage Restriction

Amylase testing does not meet coverage criteria when ordered for anything other than analysis of pancreatic cyst fluid. This restriction applies to serum amylase and all other amylase testing, including urinary amylase.

Covered indication: analysis of pancreatic cyst fluid only.
Serum, urinary, and other amylase testing outside pancreatic cyst fluid analysis is not covered.

Clinical Background

Acute pancreatitis is inflammation of pancreatic tissue that may range from mild disease to severe disease with persistent organ failure. Under the revised Atlanta classification, diagnosis is supported when at least 2 of 3 features are present: characteristic abdominal pain, serum amylase or lipase at least 3 times the upper limit of normal (ULN), or characteristic imaging findings. For symptomatic outpatient evaluation under this policy, serum lipase is the covered pancreatic enzyme test, while several other enzyme and inflammatory biomarker tests are not covered for acute pancreatitis assessment.

Definitions and Abbreviations

Definitions

AbbreviationAP

MeaningAcute pancreatitis

Clinical descriptionInflammation of the pancreatic tissue that can range in clinical manifestations

Definitions

AbbreviationCLIA '88

MeaningClinical Laboratory Improvement Amendments of 1988

Laboratory relevanceLaboratory-developed tests are regulated by CMS as high-complexity tests under CLIA '88

Covered Testing Indications

Serum Lipase Measurement

Covered for individuals presenting with signs and symptoms of acute pancreatitis, subject to the outpatient frequency limit.

Serum lipase measurement: Measurement of serum lipase meets coverage criteria for an individual presenting with signs and symptoms of acute pancreatitis.No more than one test per day in the outpatient setting

Pancreatic Cyst Fluid Amylase

Covered only for analysis of pancreatic cyst fluid.

Pancreatic cyst fluid amylase: Amylase measurement meets coverage criteria when ordered for analysis of pancreatic cyst fluid.

Amylase does not meet coverage criteria for other indications.

Evaluation of Suspected Acute Pancreatitis

Testing Frequency Limits

Serum lipase

TestSerum lipase

Frequency limitNo more than one test

Period and settingPer day in the outpatient setting

Lipase

Routine monitoringDo not routinely reorder lipase

Applies toPatients with an established diagnosis of acute or chronic pancreatitis

ExceptionRepeat testing may be appropriate when acute-on-chronic pancreatitis is clinically suspected

Ordering Requirements

Note

Order a pancreatic enzyme test within 48 hours

For suspected acute pancreatitis, test either serum amylase or serum lipase within 48 hours of admission, consistent with the AGA recommendation cited in the policy.

Noncovered Testing

The policy does not cover serum or urine trypsin, trypsinogen, or TAP or CRP, IL-6, IL-8, and procalcitonin when used for the diagnosis, assessment, prognosis, or determination of acute pancreatitis severity. It also does not cover serum lipase for situations outside the policy indications, routine repeat lipase testing to monitor established acute or chronic pancreatitis, or amylase testing other than analysis of pancreatic cyst fluid.

Policy Revision History

5/2026Coverage criteria revisionLatest

Updated the policy effective September 15, 2026 by removing duplicative criteria, limiting outpatient serum lipase testing to no more than one test per day, clarifying that amylase coverage applies to pancreatic cyst fluid rather than serum, excluding other amylase testing, and adding CPT code 86141.

8/2025Coverage criteria revision

Revised coverage criteria effective November 13, 2025 by removing amylase from acute pancreatitis diagnosis criteria, establishing a separate criterion for serum amylase outside pancreatic cyst fluid analysis as not meeting coverage criteria, and updating the background, guidelines, recommendations, and scientific references.

Policy Summary

PayerConnectiCare

PolicyPancreatic Enzyme Testing for Acute Pancreatitis

Policy CodePolicy AHS-G2153

Change TypeModified

Effective DateSeptember 15, 2026

Next Review DateNot specified

Key ActionOrder serum lipase for patients presenting with signs and symptoms of acute pancreatitis, with no more than one outpatient test per day.

SourceLink

On This Page

Clinical useSupports diagnosis of acute pancreatitis

Serum lipase and severe acute pancreatitis risk

Threshold in patients age 18 or youngerSerum lipase at least 7 times the upper limit of normal

Associated odds ratioOdds ratio of 7.1 for developing severe acute pancreatitis

Clinical limitationElevated serum lipase is not generally used to determine acute pancreatitis severity or prognosis

Serum amylase or lipase

ThresholdGreater than 3 times the upper limit of normal

TestsSerum amylase or serum lipase

Diagnostic roleBiochemical evidence supporting acute pancreatitis diagnosis

Serum CRP

Preferred levelGreater than 150 mg/L

TimingAt 48 hours after disease onset

Clinical useSeverity-related triage support as an adjunct to clinical judgment, scoring systems, and CT

Procalcitonin

ThresholdAt least 3.5 ng/mL

DurationFor at least two consecutive days

Associated conditionAcute pancreatitis associated with multiorgan dysfunction syndrome

Fecal elastase

Good evidence of exocrine pancreatic insufficiencyFecal elastase less than 100 μg/g of stool

Indeterminate result100–200 μg/g

Initial test contextFecal elastase is the most appropriate initial test in suspected exocrine pancreatic insufficiency

Serum amylase or lipase

ThresholdSerum amylase or lipase greater than or equal to 3 times the upper limit of normal

Diagnostic requirementAt least two of three diagnostic criteria must be present

Other criteriaCharacteristic abdominal pain or imaging consistent with pancreatitis

Serum triglyceride

Preferred etiologic thresholdSerum triglyceride preferably greater than 1,000 mg/dL

When to obtainIn the absence of gallstones or a significant history of alcohol use

Clinical purposeConsider the triglyceride level as a possible etiology of acute pancreatitis

Outpatient serum lipase testing

Maximum frequencyNo more than one serum lipase test per day

SettingOutpatient setting

Covered indicationIndividuals presenting with signs and symptoms of acute pancreatitis

Denial Risk

Trypsin and Trypsinogen Not Covered

Measurement of serum or urine trypsin, trypsinogen, or trypsinogen activation peptide (TAP) does not meet coverage criteria for the diagnosis, assessment, prognosis, or determination of acute pancreatitis severity.

Applies to diagnostic, assessment, prognostic, and severity-related use.

Denial Risk

Acute Pancreatitis Biomarkers Not Covered

The following biomarkers do not meet coverage criteria when used for the diagnosis, assessment, prognosis, or determination of acute pancreatitis severity: C-reactive protein, interleukin-6, interleukin-8, and procalcitonin.

C-Reactive Protein (CRP)
Interleukin-6 (IL-6)
Interleukin-8 (IL-8)
Procalcitonin

Billing Rule

Exchange Plan Applicability

These policy criteria are not applicable to Exchange Plans for dates of service on or after January 1, 2026. Verify the member's plan type and applicable benefit provisions before applying these coverage restrictions.

Exchange Plan restriction effective for dates of service on or after 2026-01-01.

Billing Rule

Outpatient Lipase Frequency Limit

In the outpatient setting, no more than one serum lipase test per day meets coverage criteria when evaluating signs and symptoms of acute pancreatitis. Additional serum lipase testing on the same day is not covered.

Outpatient frequency limit: one serum lipase test per day.
The frequency restriction applies even when the patient is being evaluated for acute pancreatitis.

Definitions

AbbreviationTAP

MeaningTrypsinogen activation peptide

Policy contextSerum or urine TAP testing does not meet coverage criteria for acute pancreatitis diagnosis, assessment, prognosis, or severity determination

Definitions

AbbreviationULN

MeaningUpper limit of normal

Diagnostic referenceAcute pancreatitis enzyme elevation is generally referenced at least 3 times the ULN

Lipase

FunctionEnzyme responsible for hydrolyzing triglycerides to aid digestion of fats

Concentration increaseIncreases within approximately 3–6 hours after pancreatic injury

Duration of elevationMay remain elevated for 1–2 weeks after acute pancreatitis onset

Hyperlipasemia

DefinitionElevated serum lipase concentration

Associated conditionMay occur in acute pancreatitis

Other reported associationMay also occur in conditions such as Gullo's syndrome

Trypsinogen

DefinitionThe zymogen form of trypsin

Site of synthesisSynthesized by pancreatic acinar cells

ActivationCleaved to form mature trypsin

Trypsin activation peptide (TAP)

DefinitionPeptide cleaved from trypsinogen during activation of trypsin

Biologic contextReleased when trypsinogen is activated to form mature trypsin

Clinical limitationUse as a diagnostic or prognostic tool for acute pancreatitis remains debated

Upper limit of normal (ULN)

DefinitionThe upper limit of the laboratory reference interval

Atlanta thresholdAt least 3 times the ULN for pancreatic enzyme elevation in acute pancreatitis

Applicable testsSerum amylase or serum lipase

Acute pancreatitis diagnostic criteria

Required number of findingsAt least 2 of 3 findings

Clinical findingCharacteristic upper abdominal pain

Biochemical or imaging findingsAmylase or lipase greater than 3 times the ULN and/or imaging confirmation of pancreatitis

SIRS

AbbreviationSIRS

MeaningSystemic inflammatory response syndrome

Policy contextPatients with unexplained multiorgan failure or SIRS should be tested for possible acute pancreatitis

Exocrine pancreatic insufficiency

High-risk conditionsChronic pancreatitis, relapsing acute pancreatitis, pancreatic ductal adenocarcinoma, cystic fibrosis, or previous pancreatic surgery

Initial testFecal elastase is the most appropriate initial test

InterpretationLess than 100 μg/g provides good evidence; 100–200 μg/g is indeterminate

Acute pancreatitis diagnostic criteria

FrameworkRevised Atlanta classification

Diagnostic requirementAt least 2 of 3 criteria

CriteriaAbdominal pain, amylase or lipase at least 3 times the ULN, or imaging consistent with pancreatitis

Enzyme threshold

ThresholdSerum amylase or lipase at least 3 times the upper limit of normal

InterpretationA level at or above this threshold is consistent with pancreatitis

Diagnostic roleCounts as the biochemical criterion in the revised Atlanta framework

Testing may be used in the evaluation of suspected acute pancreatitis when characteristic pain, biochemical evidence, or imaging findings are being assessed.

Evaluation of suspected acute pancreatitis: Evaluate suspected acute pancreatitis using serum amylase or serum lipase when characteristic abdominal pain, biochemical evidence of pancreatitis, or compatible imaging findings are being assessed.Amylase or lipase >3× ULN when biochemical evidence is present

Evaluation of Suspected Exocrine Pancreatic Insufficiency

Use fecal elastase as the initial test when exocrine pancreatic insufficiency is suspected in a high-risk patient.

High-risk clinical condition: The individual has a high-risk condition, such as chronic pancreatitis, relapsing acute pancreatitis, pancreatic ductal adenocarcinoma, cystic fibrosis, or previous pancreatic surgery.

Initial test: Fecal elastase is used as the initial test for suspected exocrine pancreatic insufficiency.

A fecal elastase level below 100 μg/g of stool provides good evidence of exocrine pancreatic insufficiency; 100–200 μg/g is indeterminate.

Revised Atlanta Evaluation of Suspected Acute Pancreatitis

Evaluate suspected acute pancreatitis under the revised Atlanta diagnostic framework.

At least 2 of 3 criteria

Characteristic abdominal pain: Abdominal pain is not attributable to another cause or is suggestive of acute pancreatitis.
Enzyme elevation: Serum lipase or, when appropriate, amylase is at least three times the upper limit of normal.≥3× ULN
Compatible imaging: Imaging is consistent with pancreatitis.

Repeat Testing for Persistent or Recurrent Disease

Repeat testing may be considered for specific clinical concerns, but not for routine monitoring.

Indications for repeat testing: There are signs or symptoms of persistent pancreatic or peripancreatic inflammation, pancreatic duct obstruction, pseudocyst development, or suspected acute-on-chronic pancreatitis.

Serum Lipase Testing for Acute Pancreatitis Symptoms

Covered for individuals presenting with signs and symptoms of acute pancreatitis, limited to one outpatient test per day.

Covered serum lipase evaluation: Evaluate an individual presenting with signs and symptoms of acute pancreatitis using serum lipase testing.No more than one test per day in the outpatient setting

Pancreatic Cyst Fluid Amylase Analysis

Covered for analysis of pancreatic cyst fluid.

Amylase measurement of pancreatic cyst fluid: Analyze pancreatic cyst fluid using amylase measurement.

The revised wording removes the serum limitation because the criterion concerns pancreatic cyst fluid.

Serum lipase

Maximum frequencyNo more than one test per day

Test and settingSerum lipase in the outpatient setting

Coverage contextApplies to individuals presenting with signs and symptoms of acute pancreatitis

11/2024Policy clarification and criteria update

Updated the policy effective March 15, 2025 to clarify that serum lipase or amylase testing is not allowed for individuals already diagnosed with acute or chronic pancreatitis, added Coverage Criterion 6, and revised the signs and symptoms in Note 1.